$OGEN early April for topline data analysis to be finalized and, soon after, be released to the press! Looking to generate revenue in a broad setting, and making deals with individual companies to provide lantibiotics while still undergoing R&D to pinpoint what proteins in the strain are most effective to treating patients. No purification or sterilization is involved since they are naturally-occuring antibiotics, therefore their profit margins will be insanely high in the manufacturing process. Im even more freaking excited for the press release!!
  • 17

    Get The Stocktwits Daily Rip

    ©2020 StockTwits, Inc. All rights reserved.
    Market Data by Xignite and BATS BZX Real-Time Price

    Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / SIPC. ST Invest is a wholly owned subsidiary of StockTwits, Inc.
    Investing in securities products involves risk, including possible loss of principal.
    Please read important legal disclosures.